Apoptosis-inducing ligands that are TRAIL-mediated in addition to caspase-associated are similar.7 Although P-gp inhibitors displayed improved efficiency in vivo and in vitro tests, the US Food and Drug Administration (FDA) has not accepted any of them for clinical usage in malignancy therapy.8 Instead, Nanayakkara et al8 proposed new P-gp inhibitors that could be useful in cancer treatment. The gene discussed is PGP; the disease is cancer.